<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
"http://www.w3.org/TR/html4/strict.dtd">
<!--[if lt IE 7 ]><html class="ie ie6" lang="en"> <![endif]-->
<!--[if IE 7 ]><html class="ie ie7" lang="en"> <![endif]-->
<!--[if IE 8 ]><html class="ie ie8" lang="en"> <![endif]-->
<!--[if (gte IE 9)|!(IE)]><!--><html lang="en"> <!--<![endif]-->
<head>

	<!-- Basic Page Needs
  ================================================== -->
    <script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/jquery-1.8.3.min.js" type="text/javascript"></script>
    <script type="text/x-mathjax-config">
	MathJax.Hub.Config({
	  "HTML-CSS": { linebreaks: { automatic: true } },
	         SVG: { linebreaks: { automatic: true } }
	});
	</script>
    <script type="text/javascript" src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
	<meta charset="utf-8">
	<title>Heart &amp; Circulation</title>
	<meta name="description" content="Course Notes for Heart &amp; Circulation">
	<meta name="author" content="Kevan Lu">
	<meta name="robots" content="noindex,nofollow"/>
	
	<!-- Mobile Specific Metas
  ================================================== -->
	<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">

	<!-- CSS
  ================================================== -->
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/layout.css">
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/content.css">
	<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/print.css">
	<link href="http://maxcdn.bootstrapcdn.com/font-awesome/4.2.0/css/font-awesome.min.css" rel="stylesheet">	
	
	<script>
		(function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
		(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
		m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
		})(window,document,'script','http://www.google-analytics.com/analytics.js','ga');		
		ga('create', 'UA-40381402-3', 'dropboxusercontent.com');
		ga('send', 'pageview');
	</script>

	<!-- Favicons
	================================================== -->
	<link rel="shortcut icon" href="https://dl.dropboxusercontent.com/u/157117/Class%20References/favicon.png" type="image/png">
</head>
<body>
    <div class="overlay"><h1><a style="border:none;" href="http://kevanlu.github.io/cardiology/index.html">Heart &amp; Circulation</a></h1></div>
    <div class="sidebar-background"></div>
    <div class="sidebar">
        <!-- Displays a Search Bar-->
<div class="search-wrapper">
	<div class="index"><a href="http://kevanlu.github.io"><i class="fa fa-stethoscope"></i> Schulich Notes</a></div>
	<form class="search" action="http://kevanlu.github.io/cardiology/search.html">
	<div style="float: left;"><input type="text" value="Search Heart &amp; Circulation" onfocus="if(this.value==this.defaultValue)this.value='';" onblur="if(this.value=='')this.value=this.defaultValue;" name="q" id="tipue_search_input"></div>
	<div style="float: left;"><input type="button" id="tipue_search_button" onclick="this.form.submit();"></div>
	<div style="clear: left;"></div>
	</form>
</div>

<div class="course-index">
	<a href="http://kevanlu.github.io/cardiology/index.html">Heart &amp; Circulation</a>
</div>

        <nav>	
	<li class="week">Week 1</li>
	<ul>
		<li class="day">January 13</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/13/intro-cardiac-physiology.html">Introduction to Cardiac Physiology</a></li></ul>
		<li class="day">January 14</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/14/intro-cardiac-physiology-2.html">Introduction to Cardiac Physiology II</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/14/heart-pump.html">The Heart as a Pump I</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/14/bp-reg-vascular-flow.html">BP Regulation &amp Vascular Flow</a></li></ul>
		<li class="day">January 15</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/15/cardiac-electrical-physiology.html">Cardiac Electrical Physiology</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/15/interpreting-ecgs-1a.html">Interpreting ECGs Ia</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/15/interpreting-ecgs-1b.html">Interpreting ECGs Ib</a></li></ul>
		<li class="day">January 16</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/16/heart-pump-2.html">The Heart as a Pump II</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/16/heart-pump-3.html">The Heart as a Pump III</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/16/anatomy-lab-heart.html">Heart Anatomy Lab</a></li></ul>
		<li class="day">January 17</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/17/intro-cardiovascular-pharmacology.html">Cardiovascular Pharmacology I</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/17/intro-cardiovascular-pharmacology-2.html">Cardiovascular Pharmacology II</a></li></ul>
	</ul>
	<li class="week">Week 2</li>
	<ul>
		<li class="day">January 20</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/20/valvular-heart-disease-cases.html">Valvular Heart Disease Cases</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/20/imaging-cardiovascular-disease.html">Imaging in Cardiovascular Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/20/into-heart-sounds.html">Introduction to Heart Sounds</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/20/clinical-assessment-heart-sounds.html">Clinical Assessment of Heart Sounds</a></li></ul>
		<li class="day">January 21</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/21/aortic-stenosis.html">Aortic Stenosis</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/21/mitral-regurgitation.html">Mitral Regurgitation</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/21/mitral-stenosis.html">Mitral Stenosis</a></li></ul>
		<li class="day">January 22</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/22/aortic-regurgitation.html">Aortic Regurgitation</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/22/endocarditis.html">Endocarditis</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/22/interpreting-ecgs-2.html">Interpreting ECGs II</a></li></ul>
		<li class="day">January 23</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/23/outline-congenital-heart-disease.html">An Outline of Congenital Heart Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/23/exercise-physiology.html">Exercise Physiology</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/23/valvular-pericardial-cases.html">Valvular Pericardial Cases</a></li></ul>
		<li class="day">January 24</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/24/surgical-management-valvular-disease.html">Surgical Management in Valvular Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/24/case-based-learning.html">Case Based Learning</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/24/clinical-problems-pediatric-cardiology.html">Clinical Problems in Pediatric Cardiology</a></li></ul>
	</ul>
	<li class="week">Week 3</li>
	<ul>
		<li class="day">January 27</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/27/case-based-learning-atherosclerosis.html">Atherosclerosis Case Based Learning</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/27/investigations-ischemic-heart-disease.html">Investigations in Ischemic Heart Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/27/vascular-pathology.html">Vascular Pathology</a></li></ul>
		<li class="day">January 28</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/28/cholinergic-pharmacology-1.html">Cholinergic Pharmacology I</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/28/physiology-hypertension.html">Physiology of Hypertension</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/28/microcirculation-physiology.html">Microcirculation Physiology</a></li></ul>
		<li class="day">January 29</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/29/pharmacology-dyslipidemia.html">Pharmacology for Dyslipidemia</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/29/lipids-genes-CAD.html">Lipids, Genes, and CAD</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/29/anatomy-lab-mediastinum.html">Mediastinum Anatomy Lab</a></li></ul>
		<li class="day">January 30</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/30/aneurysms.html">Aneurysms</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/30/case-based-learning-peripheral-vascular-disease.html">Peripheral Vascular Disease Cases</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/30/management-hypertension.html">Management of Hypertension</a></li></ul>
		<li class="day">January 31</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/31/vascular-small-group.html">Vascular Small Group Session</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/31/hypertension-small-group.html">Hypertension Small Group Session</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/01/31/cholinergic-pharmacology-2.html">Cholinergic Pharmacology II</a></li></ul>
	</ul>
	<li class="week">Week 4</li>
	<ul>
		<li class="day">Monday, February 3</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/03/primary-prevention-cardiovascular-disease.html">Primary Prevention of Cardiovascular Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/03/secondary-prevention-cardiovascular-disease.html">Secondary Prevention of Cardiovascular Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/03/management-chronic-coronary-disease.html">Management of Chronic Coronary Disease</a></li></ul>
		<li class="day">Tuesday, February 4</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/04/coronary-circulation.html">Coronary Circulation</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/04/coronary-artery-disease-mi-pci-1.html">Coronary Artery Disease &mdash; MI &amp; PCI I</a></li></ul>
		<li class="day">Wednesday, February 5</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/05/nutrition-cardiovascular-disease.html">Nutrition and Cardiovascular Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/05/ischemic-heart-disease-pathology.html">Ischemic Heart Disease Pathology</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/05/coronary-artery-disease-mi-pci-2.html">Coronary Artery Disease &mdash; MI &amp; PCI II</a></li></ul>
		<li class="day">Thursday, February 6</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/06/pediatric-cardiology.html">Child Health &mdash; Pediatric Cardiology</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/06/chest-pain-small-group.html">Chest Pain Small Group</a></li></ul>
		<li class="day">Friday, February 7</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/07/surgical-management-cardiovascular-disease.html">Surgical Management of Cardiovascular Disease</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/07/intervention-cardiac-patient-cases.html">Intervention in Cardiac Patient Cases</a></li></ul>
	</ul>
	<li class="week">Week 5</li>
	<ul>
		<li class="day">Monday, February 10</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/10/heart-failure-cases.html">Heart Failure Cases</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/10/heart-failure-1.html">Heart Failure I</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/10/physiology-heart-failure.html">Physiology of Heart Failure</a></li></ul>
		<li class="day">Tuesday, February 11</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/11/heart-failure-2.html">Heart Failure II</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/11/heart-failure-3.html">Heart Failure III</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/11/heart-failure-small-groups.html">Heart Failure Small Groups</a></li></ul>
		<li class="day">Wednesday, February 12</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/12/mechanism-arrythmia.html">Mechanism of Arrythmia</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/12/antiarrythmics.html">Antiarrythmics</a></li></ul>
		<li class="day">Thursday, February 13</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/13/atrial-fibrillation.html">Atrial Fibrillation</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/13/supraventricular-tachycardia.html">Supraventricular Tachycardia</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/13/ventricular-tachycardia.html">Ventricular Tachycardia</a></li></ul>
		<li class="day">Friday, February 14</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/14/interpreting-ecgs-3.html">Interpreting ECGs III &mdash; Cases</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/14/bradycardia.html">Bradycardia</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/14/syncope.html">Syncope</a></li></ul>
	</ul>
	<li class="week">Week 6</li>
	<ul>
		<li class="day">Tuesday, February 18</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/18/end-of-life-care.html">End of Life Care</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/18/arrythmia-small-groups.html">Arrythmia Small Groups</a></li></ul>
		<li class="day">Wednesday, February 19</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/19/ecg-exercises.html">ECG Exercises</a></li><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/19/integrated-wrap-up-cases.html">Integrated Wrap-up Cases</a></li></ul>
		<li class="day">Thursday, February 20</li>
		<ul><li class="lecture"><a href="http://kevanlu.github.io/cardiology/2014/02/20/exam-review-cardiovascular-jeopardy.html">Final Exam Review</a></li></ul>
	</ul>
</nav>
    </div>
    <div class="content-offset">
        <div class="content-background"></div>
        <div class="content">
             <div class="single post">
                <!-- Post Layout -->
                <div class="title"><h1>Cardiovascular Pharmacology I</h1></div>
                <info datetime="2014-01-17">
                    <span class="author"><a href="https://dl.dropboxusercontent.com/u/157117/notes-reference/jekyll/_site/contributors.html#kevanlu">Kevan Lu</a></span>
                    <span class="date">Friday, January 17, 2014</span>
                </info>
                <div class="body"><h3 id='drug_classes'><strong>Drug Classes</strong></h3>

<ol>
<li><strong>ACE Inhibitors (ACEI)</strong></li>

<li><strong>Angiotensin Receptor Blockers (ARB)</strong></li>

<li><strong>Aldosterone antagonists</strong></li>

<li><strong>Digoxin</strong></li>

<li><strong>Nitrates</strong></li>

<li><strong>Calcium Channel Blockers</strong></li>

<li><strong>Beta Blockers</strong></li>
</ol>

<p>For each class of drug, we will be looking at the following:</p>

<ul>
<li>Mechanism of Action</li>

<li>Indications</li>

<li>Adverse Effects</li>
</ul>

<h1 id='angiotensin_converting_enzyme_ace_inhibitors'>Angiotensin Converting Enzyme (ACE) Inhibitors</h1>
<hr /><img src='https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/5v4s5191.png' />
<p>Recall from our prior discussion of the <em>Renin/Angiotensin/Aldosterone System</em> that:</p>

<ul>
<li><em>Renin</em> is produced in the kidney, in the <em>juxtaglomerular apparatus</em></li>

<li>Renin then mediates the conversion of <em>angiotensinogen</em> to <em>angiotensin I</em>. Angiotensinogen is produced in the <em>liver</em>.</li>

<li>Angiotensin I is converted to Angiotensin II by the <strong>Angiotensin Converting Enzyme (ACE)</strong>.</li>

<li>Angiotensin II is a potent vasoconstrictor, and it also acts on the <em>adrenal cortex</em>, and triggers <em>aldosterone</em> release.</li>
</ul>

<h2 id='the_angiotensin_converting_enzyme'><strong>The Angiotensin Converting Enzyme</strong></h2>

<ol>
<li>
<p><strong>Converts Angiotensin I to Angiotensin II</strong></p>

<ul>
<li>Angiotensin II mediates aldosterone secretion and vasoconstriction, as described previously</li>

<li>It also has other effects, like <em>hypertrophy, remodeling, and fibrosis of the myocardium</em></li>

<li>It also increases <em>fluid leakage from the kidneys</em></li>

<li>It also causes <em>vasoconstriction of kidney arterioles</em></li>
</ul>
</li>

<li>
<p><strong>Converts Bradykinin to inactive peptide</strong></p>

<ul>
<li>Recall that bradykinin is an involved in the inflammatory process, and is involved in <em>vasodilation</em> and the perception of <em>pain</em></li>
</ul>
</li>
</ol>
<img src='https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/efa_q79a.png' />
<ul>
<li>
<p>Note that in the diagram, all the drugs we have act on the Angiotensin 1 receptor. There are other types of receptors that we don&#8217;t have drugs for.</p>
</li>

<li>
<p>The <strong>Angiotensin 1 Receptor</strong> downstream of Angiotensin II mediates:</p>

<ol>
<li><em>Vasoconstriction</em></li>

<li><em>&#8593; Aldosterone &#8594; Na<sup>+</sup>, H<sub>2</sub>O retention.</em></li>

<li><em>&#8593; Sympathetic Activity</em></li>
</ol>
</li>

<li>
<p>Note that since <em>ACE inhibitors</em> are more upstream along the RAAS pathway, they also affect the conversion of <em>bradykinin to inactive metabolites</em></p>
</li>

<li>
<p>Consequently, ACE inhibitors also increase bradykinin levels in the body.</p>
</li>
</ul>

<h2 id='ace_inhibitors'><strong>ACE Inhibitors</strong></h2>

<ul>
<li>
<p>ACE inhibitors generally are <strong>___ pril</strong> drugs</p>
</li>

<li>
<p>Some examples include:</p>

<ol>
<li><em>Captopril</em></li>

<li><em>Enalapril</em></li>

<li><em>Ramipril</em></li>

<li><em>Quinapril</em></li>

<li><em>Lisinopril</em></li>

<li><em>Perindopril</em></li>

<li><em>Trandolapril</em></li>

<li>&#8230; and more!</li>
</ol>
</li>

<li>
<p>As we said before, they block the <strong>Angiotensin Converting Enzyme</strong> that converts <em>Angiotensin I &#8594; Angiotensin II</em></p>
</li>

<li>
<p>Consequently, we have <em>increased angiotensin I</em>, and <em>decreased angiotensin II</em></p>
</li>

<li>
<p>As a consequence of having less Angiotensin II, we have:</p>

<ol>
<li><em>Vasodilation</em>, therefore decreased blood pressure. Since Angiotensin itself is a Vasoconstrictor!</li>

<li><em>Decreased aldosterone release</em>, increasing fluid loss from the kidneys.</li>

<li><em>Downregulation of the sympathetic nervous system</em></li>

<li><em>An effect on remodeling/hypertrophy, and myocardial fibrosis.</em></li>

<li><em>Bradykinin formation is also increased.</em> Bradykinin itself is also a vasodilator.</li>
</ol>
</li>

<li>
<p>Basically, ACE inhibitors prevent the BP maintaining effects of the RAAS system, allowing it to fall.</p>
</li>
</ul>
<img class='right' src='https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/rgfw81m_.png' />
<h4 id='indications_for_ace_inhibitors'><strong>Indications for ACE Inhibitors</strong></h4>

<ol>
<li><em>Hypertension</em>, as it is an <em>antihypertensive</em></li>

<li><em>Systolic Heart Failure</em> of all stages, as it not only reduces pressure, and hence wall tension in the LV, but it also helps prevent cardiac remodeling &#8594; improved morbidity/mortality.</li>

<li><em>Post myocardial infarction</em></li>

<li>Also used in <em>kidney disease</em> associated with diabetes &#8594; <strong>diabetic nephropathy</strong>. The idea is that ACE inhibitors start to dilate the efferent blood vessels in the kidney will decrease the pressures generated in the glomerulus and attenuate damage.</li>
</ol>

<h4 id='adverse_effects_of_ace_inhibitors'><strong>Adverse Effects of ACE Inhibitors</strong></h4>

<ol>
<li><em>Cough</em> &#8594; common, related to <em>bradykinin</em></li>

<li><em>Decreased Blood Pressure</em> &#8594; well obviously, that&#8217;s the goal.</li>

<li><em>Worsened Renal Function</em> &#8594; because of dilation of the efferent arteriole.</li>

<li><em>Hyperkalemia</em> &#8594; because of the effect on Aldosterone, which is involved in K<sup>+</sup> excretion. (affects Na<sup>+</sup>, K<sup>+</sup> pumps)</li>

<li><strong>Angioedema</strong> &#8594; localized swelling. Rare, but can be serious if it involves the face and tongue (airway obstruction). Related to bradykinin.</li>
</ol>

<h4 id='contraindications'><strong>Contraindications</strong></h4>

<ul>
<li>Patients who already have <em>high potassium</em>.</li>

<li>Patients who have <em>normal/low blood pressure</em>.</li>

<li>Patients with a <em>previous angioedema</em>.</li>

<li>Patients with a <em>cough</em> with an ACE inhibitor</li>

<li><em>Pregnancy</em>, since they seem to cause a predisposition for fetal anomalies.</li>

<li><strong>The cough and angioedema are bradykinin-related side-effects</strong></li>
</ul>

<blockquote>
<h3 id='angiotensin_converting_enzyme_ace_inhibitors'><strong>Angiotensin Converting Enzyme (ACE) Inhibitors</strong></h3>

<ul>
<li>Named <em>___ pril</em></li>
</ul>

<h5 id='mechanism_of_action'><strong>Mechanism of Action</strong></h5>

<ul>
<li>Blocks the formation of <em>Angiotensin II</em> from <em>Angiotensin I</em></li>

<li>Angiotensin II is a vasoconstrictor, increases aldosterone levels, and affects heart remodeling, hypertrophy, and fibrosis,</li>

<li>ACEI blocks this, so they cause <em>vasodilation</em>, increased <em>fluid loss from kidneys</em>, <em>reduced sympathetic activity</em>, reduced remodeling.</li>
</ul>

<h5 id='indications'><strong>Indications</strong></h5>

<ul>
<li><em>Hypertension</em></li>

<li><em>Systolic Heart Failure</em></li>

<li><em>Post Myocardial Infarction</em></li>

<li><em>Diabetic Nephropathy</em></li>
</ul>

<h5 id='contraindications'><strong>Contraindications</strong></h5>

<ul>
<li><em>Hyperkalemia</em></li>

<li><em>Normotensive/Hypotensive</em></li>

<li><em>Previous angioedema</em></li>

<li><em>Previous cough with ACEI</em></li>

<li><em>Pregnancy</em></li>
</ul>
</blockquote>

<h1 id='angiotensin_receptor_blockers_arb'>Angiotensin Receptor Blockers (ARB)</h1>
<hr />
<ul>
<li>
<p>ARBs generally are <strong>___ sartan</strong> drugs.</p>
</li>

<li>
<p>Examples include:</p>

<ul>
<li><em>candesartan</em></li>

<li><em>irbesartan</em></li>

<li><em>losartan</em></li>

<li><em>telmisartan</em></li>

<li><em>valsartan</em></li>

<li>etc.</li>
</ul>
</li>
</ul>

<h4 id='mechanism_of_action'><strong>Mechanism of Action</strong></h4>

<ul>
<li>They block the angiotensin II receptors.</li>

<li>Since they don&#8217;t block ACE, Bradykinin is still broken down!</li>

<li>Hence, they do the same things as ACEI, <em>minus the Bradykinin mediated effects</em>.</li>

<li>So they <em>still vasodilate, inhibit modeling/fibrosis, and downregulate the SNS</em></li>
</ul>
<img src='https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/efa_q79a.png' />
<h4 id='indications'><strong>Indications</strong></h4>

<ul>
<li>
<p>The <em>same indications as with ACEI!</em></p>

<ul>
<li>Hypertension</li>

<li>Heart failure</li>

<li>Myocardial infarction</li>

<li>Diabetic nephropathy</li>
</ul>
</li>

<li>
<p>However, they&#8217;re generally used if <strong>ACEI is indicated but not tolerated</strong>, such as with bradykinin-mediated effects:</p>

<ul>
<li><em>Cough</em></li>

<li><em>Angioedema</em></li>
</ul>
</li>

<li>
<p>This is because ACEI are much better studied and have a clear impact on mortality &#8212; it&#8217;s difficult to come up with an ethical trial comparing the effects of the two!</p>
</li>
</ul>

<blockquote>
<h4 id='summary'><strong>Summary</strong></h4>

<ul>
<li>ARBs do the same thing as ACEIs, but they don&#8217;t have the bradykinin mediated effects because they don&#8217;t affect ACE mediated breakdown of bradykinin.</li>

<li>Hence, they&#8217;re used in the <em>same scenarios as with ACEI</em> (CHF, diabetic nephropathy, hypertension, MI), but only if the patient has <strong>cough</strong> or <strong>angioedema</strong> from ACEI due to the bradykinin effects.</li>
</ul>
</blockquote>

<h1 id='aldosterone_antagonists_arb'>Aldosterone Antagonists (ARB)</h1>
<hr />
<ul>
<li>
<p>Aldosterone functions by:</p>

<ul>
<li>Mediating <em>salt and water renention, K<sup>+</sup> excretion.</em></li>

<li>Myocardial and vascular fibrosis.</li>
</ul>
</li>

<li>
<p>Recall that aldosterone binds to basolateral Na<sup>+</sup>/K<sup>+</sup> pumps, and upregulates their action! This ultimately increases Na reabsorption, and K efflux.</p>
</li>

<li>
<p>One aldosterone antagonist is <strong>spironolactone</strong></p>
</li>
</ul>

<h4 id='mechanism_of_action_of_spironolactone'><strong>Mechanism of action of Spironolactone</strong></h4>

<ul>
<li>Competitive antagonist to aldosterone.</li>

<li><em>&#8216;Potassium sparing diuretic&#8217;</em> since by competitively inhibiting aldosterone binding, it maintains potassium in the body.</li>

<li>This means that patients on Spironolactone are at risk for hyperkalemia!</li>
</ul>

<h4 id='indications'><strong>Indications</strong></h4>

<ul>
<li><strong>Congestive Heart Failure</strong> &#8594; shown to improve <em>morbidity and mortality</em></li>

<li>The reason for this is that, as heart failure progresses, patients tend to active the Renin-Angiotensin-Aldosterone system because of reduced cardiac output.</li>

<li>If we block some of these compensatory mechanisms, it seems as if outcomes are improved. It seems as if compensatory bodily mechanisms aim to improve short-term prognoses at the expense of long-term prognoses.</li>
</ul>

<h4 id='adverse_effects'><strong>Adverse Effects</strong></h4>

<ul>
<li>
<p><strong>Hyperkalemia</strong> &#8594; obviously, if Aldosterone binding is inhibited, systemic potassium levels are increased.</p>

<ul>
<li>Hence, if the patient has <em>renal dysfunction</em>, the use of <em>Spironolactone</em> is cautioned/contraindicated.</li>

<li>In treating a patient with hyperkalemia, stopping the drug and starting on a low potassium diet is usually the treatment. In severe hyperkalemia, <em>hemodialysis</em> is used.</li>

<li>In this case, <em>Hemodialysis</em> involves dialysis with a low potassium solution on one side, allowing for the diffusion of the high potassium out of the body.</li>
</ul>
</li>

<li>
<p><strong>Gynecomastia</strong> &#8594; Spironolactone also has anti-androgenic effects.</p>

<ul>
<li><em>Gynecomastia</em> is the formation of breats in men.</li>

<li>Obviously, this may not be very appealing.</li>
</ul>
</li>
</ul>

<h4 id='eplerenone'><strong>Eplerenone</strong></h4>

<ul>
<li><strong>Eplerenone</strong> is an aldosterone antagonist like spironolactone.</li>

<li>Has less of an anti-adrogenic effect, and therefore less gynecomastia.</li>

<li>However, it&#8217;s really expensive! <em>$3.00/day, vs &lt; 10 cents/day</em></li>
</ul>
<img class='right' src='https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/btwbttnq.png' />
<h4 id='studies_on_aldosterone_antagonists'><strong>Studies on Aldosterone Antagonists</strong></h4>

<ul>
<li>Improved mortality was shown with <em>Spironolactone</em> in a landmark study called <strong>RALES</strong>.</li>

<li>Similar results were shown in patients with more severe heart failure, in the <strong>EMPHASIS-HF</strong> trial studying Eplerenone.</li>

<li>However, as a consequence, rates of hospital admissions for <em>Hyperkalemia</em> have increased dramatically!</li>
</ul>

<blockquote>
<h4 id='summary'><strong>Summary</strong></h4>

<ul>
<li>Aldosterone antagonists (like <strong>Spironolactone</strong> and <strong>Eplerenone</strong>) are used in patients with <strong>congestive heart failure</strong>.</li>

<li>However, they increase the risk of <strong>hyperkalemia</strong>. In the case of spironolactone, it may also cause <strong>gynecomastia</strong> due to anti-androgenic effects.</li>
</ul>
</blockquote>

<h1 id='digoxin'>Digoxin</h1>
<hr />
<ul>
<li><strong>Digoxin</strong> is also known as <em>Digitalis</em>, and used to be isolated from the <em>foxglove plant</em>, or <em>Digitalis purpura</em>.</li>

<li>It is a <em>postive inotrope</em> (improves contractility).</li>

<li>Physiologically, it has two functions:</li>
</ul>
<img class='right' src='https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/o6egswv0.png' />
<ol>
<li>
<p><strong>It inhibits the Na<sup>+</sup>/K<sup>+</sup> ATPase</strong></p>

<ul>
<li>Without the Na<sup>+</sup>/K<sup>+</sup> pump, sodium accumulates in the cell.</li>

<li>As a response, the cell uses a Na<sup>+</sup>/Ca<sup>++</sup> pump, which causes an accumulation of <em>intracellar calcium</em></li>

<li><em>This increases myocardial contractility!</em></li>
</ul>
</li>

<li>
<p><strong>Indirect Vagal (PSNS) Effects</strong></p>

<ul>
<li>Recall that the vagus nerve is involved in parasympathetic function! (decreases rate of depolarization)</li>

<li>Digoxin <em>decreases the intrinsic rate of the SA node.</em></li>

<li>Also <em>decreases condution velocity through the AV node.</em> (Recall, SA &#8594; AV &#8594; His/Purkinje system)</li>

<li>Since digoxin reduces conduction through the AV node through this vagal effect, the <em>heart rate will slow</em> and improve symptoms of patients with <em>atrial fibrillation</em></li>
</ul>
</li>
</ol>

<h4 id='pharmacology'><strong>Pharmacology</strong></h4>

<ul>
<li><em>Long half life</em> (around 36 hours, 1.5 days)</li>

<li>Very <strong>narrow therapeutic ratio</strong> (you have to carefully titrate dosages!)</li>

<li>This means that if you give too much digoxin, it&#8217;ll rapidly have toxic effects!</li>

<li><strong>Renal excretion</strong>. Must manage dosage in patients with kidney failure!</li>
</ul>

<h4 id='drug_interations'><strong>Drug Interations</strong></h4>

<ul>
<li><em>Lots of drug interactions</em> (especially with an anti-arrythmic called <em>amiodarone</em>)</li>

<li>If started, can increase digoxin levels.</li>
</ul>

<h4 id='indications'><strong>Indications</strong></h4>
<img class='right' src='https://dl.dropboxusercontent.com/spa/4sm4d57annqq50o/vy8ykjad.png' />
<ol>
<li>
<p><strong>Systolic Heart Failure</strong></p>

<ul>
<li>Increased contractility (&#8217;<em>inotropy</em>&#8217;)</li>

<li><em>No overall improvement in mortality.</em></li>

<li>But <em>decreases hospital admissions!</em></li>

<li><em>Note:</em> <strong>Low doses only!</strong></li>

<li>Digoxin is basically one of the only positive-inotropes that does not have a negative effect on mortality!</li>

<li>In the past, lots of other drugs (eg. <em>phosphodiesterase inhibitors</em>), which increase cAMP intraceullarly, and improve contractility and EF, were studied.</li>

<li>They improved symptoms, but there was a dose-dependent <em>increase in mortality</em>!</li>

<li>It was as if we took a failing heart and made it work harder &#8594; but made it die earlier!</li>

<li>Because of this, physicians worried that digoxin may have been doing the same, and we had been using it for so long!</li>

<li>But studies such as the one described above showed that it had no effect on mortality.</li>
</ul>
</li>

<li>
<p><strong>Chronic Atrial Fibrillation</strong></p>

<ul>
<li>Recall, digoxin slows conduction rate through the AV node.</li>

<li>Decreases heart rate in patients with atrial fibrillation.</li>

<li>This effect is <em>very weak</em>, hence it&#8217;s not useful in patients with a high sympathetic tone, or to control HR when a patient is exercising.</li>

<li><em>The weak PSNS effect of digoxin is easily overcome by other SNS effects!</em></li>

<li>Hence, it may be better in more sedentary, older patients.</li>

<li>Also, it does <strong>not convert atrial fibrillation to sinus rhythm</strong>. Digoxin affects <em>rate control</em>, but <em>not rhythm control</em>.</li>
</ul>
</li>
</ol>

<h4 id='adverse_effects'><strong>Adverse Effects</strong></h4>

<ul>
<li>
<p>Since Digoxin messes around with Na<sup>+</sup>/K<sup>+</sup> pumps, it can cause a wide range of symptoms:</p>

<ul>
<li>Increased risk of <em>hypokalemia</em> (<strong>low</strong> potassium)</li>

<li>Increased risk of <em>any type of arrythmias</em> with digoxin toxicity.</li>

<li>Increased risk of <strong>AV blocks</strong></li>

<li>Other adverse effects include <em>nausea</em>, <em>vomiting</em>, <em>psychotic symptoms</em>, <em>yellow-green vision</em> (<strong>Xanthopsia</strong>), <em>halos in vision</em></li>
</ul>
</li>
</ul>

<blockquote>
<h4 id='summary'><strong>Summary</strong></h4>

<p>Digoxin is effectively only used in <em>two situations</em>:</p>

<ol>
<li>Slowing the heart in patients with <strong>atrial fibrillation</strong> (but no rhythm control)</li>

<li>Increasing <strong>heart contractlity.</strong> in patients with heart failure.</li>
</ol>
</blockquote>                
                </div>
            </div>
            <div class="pagination">
                <div style="width:50%; float:left;">
                     
                        <a class="newer" href="http://kevanlu.github.io/cardiology/2014/01/16/anatomy-lab-heart.html"><i class="fa fa-angle-left"></i> Heart Anatomy Lab</a> 
                     
                </div>
                <div style="width:50%; float:right;">
                     
                        <a class="older" href="http://kevanlu.github.io/cardiology/2014/01/17/intro-cardiovascular-pharmacology-2.html">Cardiovascular Pharmacology II <i class="fa fa-angle-right"></i></a> 
                     
                </div>
            </div>
        </div>
    </div>
    <script src="http://kevanlu.github.io/cardiology/index.js" type="text/javascript"></script>
<link rel="stylesheet" href="https://dl.dropboxusercontent.com/u/157117/notes/resources/stylesheets/search.css">	
<script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/tipuesearch_set.js" type="text/javascript"></script>
<script src="https://dl.dropboxusercontent.com/u/157117/notes/resources/libraries/tipuesearch.js" type="text/javascript"></script>

<script>
$(document).ready(function() {
     $('#tipue_search_input').tipuesearch();
});
</script>
</body>
</html>